Expression of kallikrein-related peptidase 7 predicts poor prognosis in patients with unresectable pancreatic ductal adenocarcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 7, 2012, Pages 1135-1142

  Iakovlev, Vladimir ^a   Siegel, Eric R ^c   Tsao, Ming Sound ^b   Haun, Randy S ^c,d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN RELATED PEPTIDASE 7; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TISSUE SECTION;

ADENOCARCINOMA; AGED; CARCINOMA IN SITU; CARCINOMA, PANCREATIC DUCTAL; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KALLIKREINS; MALE; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; PRECANCEROUS CONDITIONS; PROGNOSIS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863588450     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-1079     Document Type: Article

References (41)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36.
2. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000;6:2969-72. (Pubitemid 30637716)
3. Feldmann G, Beaty R, Hruban RH, Maitra A. Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg 2007;14:224-32. (Pubitemid 46863910)
4. Evans DB, Abbruzzese JL, Rich TA. Cancer of the Pancreas. In:DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 5th ed. Philadelphia, PA: Lippincott-Raven; 1997. p. 1054-87.
5. Shore S, Raraty MG, Ghaneh P, Neoptolemos JP. Review article: chemotherapy for pancreatic cancer. Aliment Pharmacol Ther 2003;18:1049-69. (Pubitemid 38021591)
6. Magistrelli P, Antinori A, Crucitti A, La Greca A, Masetti R, Coppola R, et al. Prognostic factors after surgical resection for pancreatic carcinoma. J Surg Oncol 2000;74:36-40. (Pubitemid 30387220)
7. Yeo CJ, Cameron JL. Prognostic factors in ductal pancreatic cancer. Langenbecks Arch Surg 1998;383:129-33. (Pubitemid 28442526)
8. You DD, Lee HG, Heo JS, Choi SH, Choi DW. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. J Gastrointest Surg 2009;13:1699-706.
9. Smith RA, Tang J, Tudur-Smith C, Neoptolemos JP, Ghaneh P. Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer 2011;104:1440-51.
10. Johnson SK, Ramani VC, Hennings L, Haun RS. Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin. Cancer 2007;109:1811-20. (Pubitemid 46668545)
11. Egelrud T. Purification and preliminary characterization of stratum corneum chymotryptic enzyme: a proteinase that may be involved in desquamation. J Invest Dermatol 1993;101:200-4. (Pubitemid 23218699)
12. Hansson L, Strömqvist M, Bäckman A, Wallbrandt P, Carlstein A, Egelrud T. Cloning, expression, and characterization of stratum corneum chymotryptic enzyme: a skin-specific human serine proteinase. J Biol Chem 1994;269:19420-6.
13. Kyriakopoulou LG, Yousef GM, Scorilas A, Katsaros D, Massobrio M, Fracchioli S, et al. Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. Clin Biochem 2003;36:135-43. (Pubitemid 36287493)
14. Tanimoto H, Underwood LJ, Shigemasa K, Yan Yan MS, Clarke J, Parmley TH, et al. The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer 1999;86:2074-82.
15. Santin AD, Cane S, Bellone S, Bignotti E, Palmieri M, De Las Casas LE, et al. The serine protease stratum corneum chymotryptic enzyme (kallikrein 7) is highly overexpressed in squamous cervical cancer cells. Gynecol Oncol 2004;94:283-8. (Pubitemid 39024528)
16. Talieri M, Diamandis EP, Gourgiotis D, Mathioudaki K, Scorilas A. Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. Thromb Haemost 2004;91:180-6. (Pubitemid 38111235)
17. Al-Aynati MM, Radulovich N, Riddell RH, Tsao M-S. Epithelial-cadherin and {beta}-catenin expression changes in pancreatic intraepithelial neoplasia. Clin Cancer Res 2004;10:1235-40. (Pubitemid 38365212)
18. Takikita M, Altekruse S, Lynch CF, Goodman MT, Hernandez BY, Green M, et al. Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue microarray. Cancer Res 2009;69:2950-5.
19. Iakovlev VV, Gabril M, Dubinski W, Scorilas A, Yousef YM, Faragalla H, et al. Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study. Lab Invest 2012;92:46-56.
20. Iakovlev VV, Pintilie M, Morrison A, Fyles AW, Hill RP, Hedley DW. Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX. Lab Invest 2007;87:1206-17. (Pubitemid 350126705)
21. Hedley D, Pintilie M, Woo J, Morrison A, Birle D, Fyles A, et al. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin Cancer Res 2003;9:5666-74. (Pubitemid 37499489)
22. Hedley D, Pintilie M, Woo J, Nicklee T, Morrison A, Birle D, et al. Up-regulation of the redox mediators thioredoxin and apurinic/apyrimidinic excision (APE)/Ref-1 in hypoxic microregions of invasive cervical carcinomas, mapped using multispectral, wide-field fluorescence image analysis. Am J Pathol 2004;164:557-65. (Pubitemid 38364671)
23. Agresti A. Generalized Mantel tests. Categorical data analysis. New York: John Wiley & Sons; 1990. p. 286-7.
24. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 2001;22:184-204. (Pubitemid 32458158)
25. Borgono CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004;2:257-80. (Pubitemid 39031076)
26. Paliouras M, Borgono C, Diamandis EP. Human tissue kallikreins: the cancer biomarker family. Cancer Lett 2007;249:61-79. (Pubitemid 46427999)
27. Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol Chem 2010;391:505-11.
28. Emami N, Diamandis EP. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin Chem 2008;54:1600-7.
29. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16. (Pubitemid 17147932)
30. Termini L, Maciag PC, Soares FA, Nonogaki S, Pereira SM, Alves VA, et al. Analysis of human kallikrein 7 expression as a potential biomarker in cervical neoplasia. Int J Cancer 2010;127:485-90.
31. Maitra A, Adsay NV, Argani P, Iacobuzio-Donahue C, De Marzo A, Cameron JL, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 2003;16:902-12. (Pubitemid 37152020)
32. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004;303:1483-7. (Pubitemid 38314410)
33. Inoue Y, Yokobori T, Yokoe T, Toiyama Y, Miki C, Mimori K, et al. Clinical significance of human kallikrein7 gene expression in colorectal cancer. Ann Surg Oncol 2010;17:3037-42.
34. Talieri M, Li L, Zheng Y, Alexopoulou DK, Soosaipillai A, Scorilas A, et al. The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. Br J Cancer 2009;100:1659-65.
35. Talieri M, Mathioudaki K, Prezas P, Alexopoulou DK, Diamandis EP, Xynopoulos D, et al. Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. Thromb Haemost 2009;101:741-7.
36. Prezas P, Scorilas A, Yfanti C, Viktorov P, Agnanti N, Diamandis E, et al. The role of human tissue kallikreins 7 and 8 in intracranial malignancies. Biol Chem 2006;387:1607-12. (Pubitemid 44837586)
37. Zhao H, Dong Y, Quan J, Smith R, Lam A, Weinstein S, et al. Correlation of the expression of human kallikrein-related peptidases 4 and 7 with the prognosis in oral squamous cell carcinoma. Head Neck 2011;33:566-72.
38. Ramani VC, Haun RS. Expression of kallikrein 7 diminishes pancreatic cancer cell adhesion to vitronectin and enhances urokinase-type plasminogen activator receptor shedding. Pancreas 2008;37:399-404.
39. Ramani VC, Hennings L, Haun RS. Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer. BMC Cancer 2008;8:373.
40. Ramani VC, Haun RS. The extracellular matrix protein fibronectin is a substrate for kallikrein 7. Biochem Biophys Res Commun 2008;369:1169-73.
41. Ramani VC, Kaushal GP, Haun RS. Proteolytic action of kallikrein-related peptidase 7 produces unique active matrix metalloproteinase-9 lacking the C-terminal hemopexin domains. Biochim Biophys Acta 2011;1813:1525-31.